List

[This review was originally posted at the Nieman Journalism Lab Cephalexin For Sale, on Nov. 11, 2011.]

Google+ courts businesses: After banning businesses for its first four months, Google+ finally let them in this week, launching Google+ Pages, which gives accounts to business and groups. (Danny Sullivan of Search Engine Land put together the best walkthrough of what Pages are and how they work.) Businesses jumped right in, including, About Cephalexin, of course, news orgs: Breaking News put together a running list of news Pages, and one Fox News show announced it would do Hangouts with presidential candidates, starting with Mitt Romney next week.

As Business Insider explained, Google has a big carrot to draw businesses in: Direct Connect, which allows users to go directly to a business's Google+ Page if they the business's name preceded by a "+". Lost Remote's Cory Bergman (who also runs the Breaking News Google+ account) said businesses should also get some SEO mojo from users clicking +1 on their Google+ account, which he argued was enough of a payoff to justify maintaining a Google+ account — at least for now, Cephalexin over the counter, anyway.

Social media guru Robert Scoble, on the other hand, was disappointed in Pages, calling them clumsy and difficult to manage, Cephalexin For Sale. Fast Company's Mark Wilson brought up the same point and added that since Google gives individuals two options of how to engage with businesses instead of Facebook's single "Like," most people will choose the weaker option. TechCrunch's Jason Kincaid wondered what exactly that weaker option, giving the business a +1, will do.

For Slate's Farhad Manjoo, Doses Cephalexin work, the addition of Pages was too little, too late for Google+. He declared the social network dead, a victim of Google's launch-then-fix-it model that has worked so well for most of its products. "But a social network isn’t a product; it’s a place Cephalexin For Sale, ," Manjoo wrote, arguing that Google should have let its users be more free to experiment to make up for its initial deficits. Mathew Ingram of GigaOM and the New York Times' Nick Bilton countered that it's too soon to give up on the network, because Google+ is designed to be not just another social network, but instead the connective tissue integrating an entire way to experience the web. Google has some pretty good cards still its hand that can help it reach that goal, too, he said.

Romenesko, attribution, and hair-splitting: Jim Romenesko, the dean of media bloggers soon to semi-retire from the Poynter Institute, was pushed into a bizarre little controversy yesterday when his editor, Cephalexin without prescription, Julie Moos, wrote a post taking him to task for "incomplete attribution" in his posts — essentially, using language from the posts he's summarizing (and linking to) without putting it in quote marks. Moos wrote the post in response to questions from the Columbia Journalism Review as it develops an article on the subject.

Romenesko wasn't asked to resign (he offered his resignation twice but Moos rejected it), but he will have to follow stricter attribution guidelines and have his posts edited before they go up. 10, Is Cephalexin addictive, 000 Words' Elena Zak praised Poynter's transparency, but to most observers, this was ethical hairsplitting run amok.

Media consultant Mark Potts hit many of the main points in his defense of Romenesko, noting that no one has complained to Poynter about this in the decade he's been blogging for them. Reuters' Felix Salmon pointed to Romenesko's stature in the blogosphere and his role in establishing the field's norms: "If your guidelines go against what Jim is doing, then there might well be something wrong with your guidelines."

The Awl's Choire Sicha took the opportunity to level a more serious charge at Poynter's handling of Romenesko's blog, saying that "Poynter has worked systematically to erode a fairly noble, not particularly money-making thing as it works to boost 'engagement'" and other online-media buzzwords, Cephalexin For Sale. For his part, Romenesko himself expressed his frustration in typically understated fashion in an email to the New York Times, then tweeted that "I feel it's time to go."

Is future-of-news talk hurting journalism?: This week, we got the rare opportunity to have a substantive, big-picture (meta)discussion about the way we think about the future of news when the Columbia Journalism Review published a thorough critique by Dean Starkman of 'future of news' thinkers like Jeff Jarvis, Clay Shirky, Cephalexin alternatives, and Jay Rosen.

The piece is quite long, but worth a close read: In short, Starkman argued that these thinkers are undermining the most valuable form of journalism — public-service journalism — by disempowering journalists and their institutions and by wasting their limited time (and the public's) with endless, mostly useless experimentation and busywork. Instead, Starkman proposed a model built around maintaining journalism's most valued institutions, Buy Cephalexin without a prescription, arguing that "journalism needs its own institutions for the simple reason that it reports on institutions much larger than itself."

Several people objected to Starkman's argument, starting with media strategist Terry Heaton, who countered that it's not institutions the future-of-news people have a problem with, but hierarchical institutions, and former Wall Street Journal writer Jason Fry, who said that some forms of news are indeed a commodity. A few others, like Mathew Ingram of GigaOM and Steve Buttry of the Journal Register Co. Cephalexin For Sale, argued that deep reporting vs. new media mastery isn't an either/or proposition, Cephalexin no prescription, pointing to examples of news organizations like the Guardian who do both well.

Former Guardian digital editor Emily Bell also wrote about her old paper's efforts in making a similar point, arguing that the spirit of muckraking is being carried on in these digital, networked initiatives. "The opening of electronic ears and eyes is not a replacement for reporting. It should be at the heart of it. And if it is not, then the institutions that Starkman laments might be to blame," she wrote, Cephalexin For Sale. Starkman responded by arguing that it all boils down to stories, Cephalexin maximum dosage, but the future-of-news folks want to talk about something else, and here at the Lab, C.W. Anderson weighed in on with a smart post on the ways in which institutions can be forces for both good and ill.

A force for digital change in the newsroom: The New York Times announced this week the retirement (effective the end of the year) of one of the pioneers of news on the web — Martin Nisenholtz, a senior vice president at the paper. As the Times noted, Nisenholtz has been intimately involved in just about every major technological initiative the Times has undertaken since he came on board in 1995: Launching the website, moving it into mobile media and tablets, Cephalexin description, and instituting its paywall earlier this year.

Poynter's Julie Moos put together a greatest-hits of commentary Cephalexin For Sale, by and about Nisenholtz over the years, including his prediction in early 2004 that smart phones would be a particularly influential force in changing news delivery. PaidContent's Staci Kramer talked about his lasting impact: No matter how slow (or fast) the transition seemed, "the NYT has an integrated newsroom with an understanding that digital, while it may not always be first, is equal."

Dave Winer, who helped create RSS, pointed out that Nisenholtz made the Times the first major publisher to license its stories for RSS, Cephalexin images, making a significant contribution to the growth of the open web in the process. The Lab's Joshua Benton used that story to illustrate thateven if news orgs can't invent these transformative web tools, they can still play a big role in their evolution and adoption. Media prof C.W. Anderson also noted another contribution Nisenholtz made — by allowing a scholar access to study his paper's digital efforts, he helped revitalize the field of digital media sociology.

A neutral way to tweet: If a few of the most recent sets of social media guidelines are any indication, news organizations are really struggling with the concept of their journalists' retweets on Twitter, Cephalexin For Sale. Several of those organizations have asked journalists not to retweet opinionated content without comment, lest they be thought of as biased themselves. Poynter's Jeff Sonderman tried to resolve that problem with an idea for an NT, Cephalexin from mexico, or neutral tweet, which people could use to retweet something while declaring their neutrality about it.

Most journalism folks on Twitter didn't like the idea, as Sonderman himself showed in his fine roundup of reaction. Many of them saw it as a way to avoid interacting naturally on Twitter, a "pacifier" or "high tech milquetoast," in the words of j-profs Jay Rosen and Matt Waite. Cephalexin For Sale, GigaOM's Mathew Ingram expanded on the idea, calling it a solution to the wrong problem. "By pretending that their journalists don’t have opinions, when everyone knows that they do, mainstream media outlets are suggesting their viewers or readers are too stupid to figure out where the truth lies," he wrote. Buy no prescription Cephalexin online,

Reading roundup: Lots of smaller stories and discussions popping in and out of the future-of-news world this week. Here's a few of them:

— This week in News Corp. scandal: Rupert Murdoch's son, James, told British Parliament he didn't mislead them last time he talked to them. Or, as Gawker put it, he asserted that everyone's a liar except him. The Guardian's Roy Greenslade doesn't believe him, Cephalexin For Sale. Murdoch also said the company might still close its British newspaper, Cephalexin canada, mexico, india, the Sun. And we also found out News of the World hired people to spy on their hacking victims' lawyers. Guardian editor Alan Rusbridger put the scandal in perspective in a lecture.

— New York Times media critic David Carr mused on the decline of WikiLeaks as an organization and its implications for radical transparency as a movement. Dave Winer and Mathew Ingram responded by questioning why the Times hasn't supported WikiLeaks more itself.

— Andy Rooney of CBS' 60 Minutes, one of the icons of American broadcast television, died late last week at age 92. Cephalexin recreational, You can check out the obituaries from CBS and the New York Times, a set of his classic essays at Gawker, and a thoughtful remembrance by tech entrepreneur Anil Dash.

— Finally, two great pieces of advice for two groups of people: Longtime News & Record editor John Robinson for newspaper editors, and MIT's Ethan Zuckerman for media consumers (read: all of us).

Similar posts: Armour For Sale. Buy Glucophage No Prescription. Tramadol No Rx. Cipro pictures. Tramadol pharmacy. Buy cheap Armour no rx.
Trackbacks from: Cephalexin For Sale. Cephalexin For Sale. Cephalexin For Sale. Purchase Cephalexin online. Real brand Cephalexin online. About Cephalexin.

  Posts

August 28th, 2014

This Week in Review: Twitter and press intimidation in Ferguson, and a journalist’s brutal execution

August 21st, 2014

This Week in Review: Ferguson and press freedom, and BuzzFeed’s $50 million boost

August 14th, 2014

This Week in Review: Covering war in real time, and evaluating a pair of plagiarism cases

July 31st, 2014

This Week in Review: The Fox/Time Warner dance begins, and clickbait and its discontents

July 17th, 2014

This Week in Review: Facebook and online control, and educating stronger data journalists

July 10th, 2014

This Week in Review: Questions on Facebook’s experiment, and a knockout blow to Aereo

July 2nd, 2014

This Week in Review: Time Inc. tries to survive on its own, and the global shift to mobile news

June 12th, 2014

This Week in Review: A setback for reporter privilege, and a new New York Times opinion app

June 9th, 2014

Making sense of research: Has campaign journalism changed on Twitter?

June 5th, 2014

This Week in Review: Kinsley vs. Greenwald on NSA secrets, and new data on mobile’s rise